Lv Shanshan, Zhao Jiao, Xi Lei, Lin Xiaoyun, Wang Chun, Yue Hua, Gu Jiemei, Hu Weiwei, Fu Wenzhen, Wei Zhanying, Zhang Hao, Hu Yunqiu, Li Shanshan, Zhang Zhenlin
Shanghai Clinical Research Center of Bone Disease, Department of Osteoporosis and Bone Disease, Shanghai Jiao Tong University Affiliated Sixth People's Hospital, Shanghai, China.
Front Cell Dev Biol. 2021 Sep 7;9:715042. doi: 10.3389/fcell.2021.715042. eCollection 2021.
Genetic skeletal dysplasias (GSDs) are a type of disease with complex phenotype and high heterogeneity, characterized by cartilage and bone growth abnormalities. The variable phenotypes of GSD make clinical diagnosis difficult. To explore the clinical utility of targeted exome sequencing (TES) in the diagnosis of GSD, 223 probands with suspected GSD were enrolled for TES with a panel of 322 known disease-causing genes. After bioinformatics analysis, all candidate variants were prioritized by pathogenicity. Sanger sequencing was used to verify candidate variants in the probands and parents and to trace the source of variants in family members. We identified the molecular diagnoses for 110/223 probands from 24 skeletal disorder groups and confirmed 129 pathogenic/likely pathogenic variants in 48 genes. The overall diagnostic rate was 49%. The molecular diagnostic results modified the diagnosis in 25% of the probands, among which mucopolysaccharidosis and spondylo-epi-metaphyseal dysplasias were more likely to be misdiagnosed. The clinical management of 33% of the probands also improved; 21 families received genetic counseling; 4 families accepted prenatal genetic diagnosis, 1 of which was detected to carry pathogenic variants. The results showed that TES achieved a high diagnostic rate for GSD, helping clinicians confirm patients' molecular diagnoses, formulate treatment directions, and carry out genetic counseling. TES could be an economical diagnostic method for patients with GSD.
遗传性骨骼发育不良(GSDs)是一类具有复杂表型和高度异质性的疾病,其特征为软骨和骨骼生长异常。GSDs的可变表型使得临床诊断困难。为了探索靶向外显子组测序(TES)在GSD诊断中的临床应用价值,对223例疑似GSD的先证者进行了TES检测,检测基因包括322个已知致病基因。经过生物信息学分析,所有候选变异根据致病性进行优先级排序。采用Sanger测序法验证先证者及其父母中的候选变异,并追踪家庭成员中变异的来源。我们从24个骨骼疾病组中为110/223例先证者确定了分子诊断结果,并在48个基因中确认了129个致病/可能致病的变异。总体诊断率为49%。分子诊断结果使25%的先证者诊断得以修正,其中黏多糖贮积症和脊椎骨骺干骺端发育不良更容易被误诊。33%的先证者的临床治疗也得到了改善;21个家庭接受了遗传咨询;4个家庭接受了产前基因诊断,其中1个被检测出携带致病变异。结果表明,TES对GSD具有较高的诊断率,有助于临床医生确认患者的分子诊断、制定治疗方向并开展遗传咨询。TES可能是一种经济的GSD患者诊断方法。